Pawtucket, RI, United States of America

Steven Michael Opal


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Steven Michael Opal: Innovator in Pharmaceutical Treatments

Introduction

Steven Michael Opal is a notable inventor based in Pawtucket, RI (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of sepsis. His innovative approach combines antibodies to enhance therapeutic outcomes for patients suffering from this serious condition.

Latest Patents

Steven Michael Opal holds a patent for a pharmaceutical product aimed at treating sepsis. This patent involves the use of an antibody to tumor necrosis factor-α (anti-TNF) and an antibody to bacterial lipopolysaccharide (anti-LPS). The combination of these antibodies has been shown to improve survival rates in a neutropenic rat model of sepsis compared to using either antibody alone. This advancement highlights the potential utility of these pharmaceutical products in sepsis therapy.

Career Highlights

Throughout his career, Steven has focused on developing innovative solutions in the pharmaceutical industry. His work has been instrumental in advancing treatments that address critical health challenges. He is currently associated with Solvay SA, where he continues to contribute to the field.

Collaborations

Steven has collaborated with esteemed colleagues, including Jerald C Sadoff and Alan S Cross. These partnerships have fostered a collaborative environment that enhances research and development efforts in pharmaceutical innovations.

Conclusion

Steven Michael Opal's contributions to the field of pharmaceuticals, particularly in sepsis treatment, underscore his role as an influential inventor. His innovative patent and collaborative efforts reflect a commitment to improving patient outcomes through advanced therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…